The FDA approved Viridian Therapeutics’ thyroid eye disease drug veligrotug, to be marketed as Lumvoa, setting up direct competition with Amgen’s Tepezza. The approval opens a new pricing and access contest in a niche but commercially important ophthalmology segment. Viridian’s CEO described the pricing strategy as aiming to be “in line with” Tepezza, and the launch timing increases pressure on payers and providers to reassess treatment algorithms for thyroid eye disease. Clinically, the approval matters because thyroid eye disease remains an area with unmet need and significant variation in treatment response, making real-world selection of options a key market driver.